The trials and tribulations of treating clostridium difficile infection - One step backward, one step forward, but still progress

Clinical Infectious Diseases

Volumn 59, Issue 3, 2014, Pages 355-357

  Wilcox, Mark H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Diarrhea; Metronidazole; Tolevamer; Toxin; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; METRONIDAZOLE; VANCOMYCIN;

CLOSTRIDIUM INFECTIONS; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMAN; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; VANCOMYCIN;

EID: 84905024929     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu316     Document Type: Editorial

References (25)

1. Gerding DN Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis 2005; 40: 1598-600.
2. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials Clin Infect Dis 2014; 3: 345-54.
3. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 411-20.
4. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
5. Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 56-62.
6. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36: 673-9.
7. Lahue BJ, Davidson DM. Metronidazole and vancomycin outcomes for Clostridium difficile-associated disease in a US hospital database. In: ECCMID. Munich, 2007. Abstract O331.
8. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
9. Debast SB, Bauer MP, Kuijper EJ; Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 (SUPPL. 2): 1-26.
10. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-72.
11. Baird D. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother 1989; 23: 167-9.
12. Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
13. Moura I, Spigaglia P, Barbanti F, Mastrantonio P. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes. J Antimicrob Chemother 2013; 68: 362-5.
14. Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006; 44: 353-8.
15. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001; 45: 2340-7.
16. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralisation of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 2202-4.
17. Best EL, Freeman J, Wilcox MH. Models for the study of Clostridium difficile infection. Gut Microbes 2012; 3: 145-67.
18. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
19. Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis 2013; 13: 936-45.
20. Walker AS, Eyre DW, Wyllie DH, et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013; 56: 1589-600.
21. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50: 194-201.
22. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
23. Gorbach SL Drugs for your mother-in-law, not your mother. Infect Dis Clin Pract 1992; 1: 46.
24. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55 (SUPPL. 2): S88-92.
25. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of hospital onset health care facility acquired Clostridium difficile infection in Europe: a systematic review. J Hops Infect 2012; 81: 1-14.